Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 107 record(s)

Req # A-2020-001715

Adverse Reaction Reports (AERs). Report numbers: 000909929, E2B_03063210, E2B_03062611, E2B_03048826, E2B_03114562, E2B_03121523, E2B_03121652, E2B_03143606, E2B_03177135, E2B_03196748, E2B_03204305, E2B_03204619, E2B_03197922, E2B_02283420, E2B_03224385, E2B_03257773, E2B_03260352.

Organization: Health Canada

243 page(s)
May 2021

Req # A-2020-001722

Adverse Reaction Reports (AERs). Report numbers: E2B_03033050, E2B_03316269, E2B_03320853, E2B_03380736.

Organization: Health Canada

50 page(s)
May 2021

Req # A-2020-001744

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_02944156.

Organization: Health Canada

43 page(s)
May 2021

Req # A-2020-001761

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03470442.

Organization: Health Canada

13 page(s)
May 2021

Req # A-2020-001765

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03481143.

Organization: Health Canada

9 page(s)
May 2021

Req # A-2020-001766

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03481161.

Organization: Health Canada

9 page(s)
May 2021

Req # A-2020-001770

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03497961.

Organization: Health Canada

32 page(s)
May 2021

Req # A-2020-001799

Adverse Reaction Reports (AERs). Report numbers: E2B_03268688, E2B_03338192, 000926187, E2B_03411602, E2B_03410952.

Organization: Health Canada

58 page(s)
May 2021

Req # A-2020-001810

Adverse Reaction Reports (AERs). Report numbers: E2B_03183672, E2B_03183681, E2B_03181774, E2B_03300959, E2B_03280997, E2B_03288062, E2B_03309044.

Organization: Health Canada

75 page(s)
May 2021

Req # A-2020-001814

Adverse Reaction Report (AER) for pms-Olanzapine. Report number: E2B_02752403. ADR for Chewable daily low dose ASA. Report number: E2B_02628495. ADR for pms-Valacyclovir. Report number: E2B_02733825.

Organization: Health Canada

57 page(s)
May 2021
Date modified: